Showing 4111-4120 of 5646 results for "".
- Atsena Therapeutics Announces Positive Results from Phase 1/2 Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)https://modernod.com/news/atsena-therapeutics-announces-positive-results-from-phase-iii-clinical-trial-of-atsn-101-for-the-treatment-of-gucy2d-associated-leber-congenital-amaurosis-lca1/2481145/Atsena Therapeutics announced positive results from the phase 1/2 clinical trial of ATSN-101, its lead investigational gene therapy product formerly known as SAR439483, for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). The data demonstrated that su
- MYZE Eye Health Focused Digital Platform Launchedhttps://modernod.com/news/myze-eye-health-focused-digital-platform-launched/2481138/MYZE is a eye care engagement platform designed to help identify, treat, and manage dry eyes. It is designed to simplify the burden of dry eye identification and management by enabling “always available” screenings followed by frictionless access to products, servi
- Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meetinghttps://modernod.com/news/glaukos-technologies-featured-in-numerous-scientific-abstracts-at-the-2022-american-academy-of-ophthalmology-annual-meeting/2481136/Glaukos announced that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held September 30-October 3, 2022 in Chicago. Key Glaucoma Presentations: Bryan CH Ang, MD Novel
- Ocuphire Expands Medical Advisory Board with Seven New KOLs; Expands Leadership Teamhttps://modernod.com/news/ocuphire-expands-medical-advisory-board-with-seven-new-kols-expands-leadership-team/2481132/Ocuphire Pharma announced that it has appointed seven new key opinion leaders (KOLs) across retina, cornea/refractive, and medical optometry to its Medical Advisory Board (MAB). In addition, Ronil Patel, MS, has been promoted to Vice President, Business Development and Market St
- Johnson & Johnson Vision Introduces Tecnis Symfony OptiBlue EDOF IOL, the Latest PC-IOL Powered by InteliLight Technologyhttps://modernod.com/news/johnson-johnson-vision-introduces-tecnis-symfony-optiblue-edof-iol-the-latest-pc-iol-powered-by-intelilight-technology/2481128/Johnson & Johnson Vision announced availability of a new presbyopia-correcting IOL (PC-IOL) powered by InteliLight technology, Tecnis Symfony OptiBlue IOL. This extended depth-of-focus (EDOF) lens expands presbyopia correction to more patients and joins Tecnis Synergy IOL, a hi
- Johnson & Johnson Vision Expands Access to Myopia Management for More Patients With Abiliti Overnight Lenseshttps://modernod.com/news/johnson-johnson-vision-expands-access-to-myopia-management-for-more-patients-with-abiliti-overnight-lenses/2481127/Johnson & Johnson Vision announced FDA approval of an expanded range of ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management, now up to 6.00 diopters (previously 4.00 diopters). Johnson & Johnson Vision also announced greater availability of the lenses nationwi
- Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the Omni Surgical System as a Standalone Glaucoma Treatment at AAOhttps://modernod.com/news/sight-sciences-to-feature-interactive-panel-discussions-of-real-world-use-of-the-omni-surgical-system-as-a-standalone-glaucoma-treatment-at-aao/2481125/Sight Sciences announced that 12 ophthalmic physicians will present their first-hand experience using the Omni Surgical System as a standalone minimally invasive glaucoma surgery (MIGS) during this year’s annual AAO convention at McCormick Place in Chicago. Meeting delegates are invite
- Visus Therapeutics Acquires Assets of ViewPoint Therapeuticshttps://modernod.com/news/visus-therapeutics-acquires-assets-of-viewpoint-therapeutics/2481124/Visus Therapeutics announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics. Financial terms of the deal were not disclosed. Founded in 2014, ViewPoint discovered and developed alpha-crystallin aggregation
- Tarsus Presents Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Datahttps://modernod.com/news/tarsus-to-present-saturn-2-pivotal-phase-3-trial-data-and-saturn-1-extension-study-long-term-safety-data-at-upcoming-eye-care-meetings/2481123/Tarsus Pharmaceuticals announced that the results from the Saturn-2 pivotal phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) in Demodex blepharitis patients will be presented at the upcoming World Cornea Congress (WCC) VIII and the American Academy of Ophthalmology
- Ocular Therapeutix Announces Interim 7-month Data from US Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-interim-7-month-data-from-us-phase-1-clinical-trial-of-otx-tki-for-the-treatment-of-wet-amd/2481120/Ocular Therapeutix announced interim 7-month data from its US phase 1 clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases. The data will b